CSIMarket
 


Nature s Sunshine Products inc   (NATR)
Other Ticker:  
 
 

NATR's Net Income Growth by Quarter and Year

Nature S Sunshine Products Inc 's Net Income results by quarter and year




NATR Net Income (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter December - 9.34 2.08 13.80
III Quarter September - 3.14 0.20 5.46
II Quarter June 1.49 2.68 0.95 6.79
I Quarter March 2.49 1.25 -2.69 4.15
FY   3.98 16.41 0.54 30.20



NATR Net Income second quarter 2024 Y/Y Growth Comment
Nature S Sunshine Products Inc reported fall in Net Income in the second quarter 2024 by -44.48% to $ 1.49 millions, from the same quarter in 2023.
The drop in the second quarter 2024 Nature S Sunshine Products Inc 's Net Income compares unfavorably to the Company's average Net Income jump of 68.95%.

Looking into second quarter 2024 results within Major Pharmaceutical Preparations industry 5 other companies have achieved higher Net Income growth. While Nature S Sunshine Products Inc ' s Net Income drop of -44.48% ranks overall at the positon no. 289 in the second quarter 2024.




NATR Net Income ( Y/Y Growth %) 2024
2023 2022 2021
IV Quarter December - 349.04 % -84.93 % 107.52 %
III Quarter September - 1470 % -96.34 % -23.85 %
II Quarter June -44.48 % 182.11 % -86.01 % 10.77 %
I Quarter March 99.2 % - - 37.87 %
FY   - 2938.89 % -98.21 % 31.53 %

Financial Statements
Nature S Sunshine Products Inc 's second quarter 2024 Net Income $ 1.49 millions NATR's Income Statement
Nature S Sunshine Products Inc 's second quarter 2023 Net Income $ 2.68 millions Quarterly NATR's Income Statement
New: More NATR's historic Net Income Growth >>


NATR Net Income (Quarter on Quarter Growth %)

2024
2023 2022 2021
IV Quarter December - 197.45 % 940 % 152.75 %
III Quarter September - 17.16 % -78.95 % -19.59 %
II Quarter June -40.24 % 114.4 % - 63.61 %
I Quarter March -73.34 % -39.9 % - -37.59 %
FY (Year on Year)   - 2938.89 % -98.21 % 31.53 %




Net Income second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #6
Healthcare Sector #30
Overall #289

Net Income Y/Y Growth Statistics
High Average Low
2884.73 % 68.95 % -300.8 %
(Dec 31 2023)   (Sep 30 2018)
Net Income second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #6
Healthcare Sector #30
Overall #289
Net Income Y/Y Growth Statistics
High Average Low
2884.73 % 68.95 % -300.8 %
(Dec 31 2023)   (Sep 30 2018)

Net Income by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Nature S Sunshine Products Inc 's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
5004.35 % 176.04 % -97.53 %
(Sep 30 2017)  


NATR's II. Quarter Q/Q Net Income Comment
In the II. Quarter 2024 Nature S Sunshine Products Inc reported fall in Net Income from the previous quarter by -40.24% to $ 1.49 millions, from $ 2.49 millions achived a quarter before.

Albeit seasonal influence normally elevate II. Quarter 2024 Net Income, it plainly has not been enough to rescue NATR's II. Quarter 2024 achievement, Angelina Lyons, Healthcare sector veteran wrote and continued that average sequential Net Income growth is at 176.04% for Nature S Sunshine Products Inc .

Within Major Pharmaceutical Preparations industry 13 other companies have achieved higher Net Income quarter on quarter growth. While Nature S Sunshine Products Inc 's Net Income growth quarter on quarter, overall rank is 1156.


Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #14
Healthcare Sector #73
Overall #1156
Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #14
Healthcare Sector #73
Overall #1156
Net Income Q/Q Growth Statistics
High Average Low
5004.35 % 176.04 % -97.53 %
(Sep 30 2017)  


NATR's II. Quarter Q/Q Net Income Comment
In the II. Quarter 2024 Nature S Sunshine Products Inc disclosed fall in Net Income from the first quarter by -40.24% to $ 1.49 millions, from $ 2.49 millions declared in the previous reporting period.

Albeit cyclical circumstance normally elevate II. Quarter 2024 results, it plainly was not enough to recover NATR's II. Quarter achievement, Angelina Lyons, Healthcare sector veteran wrote.

Within Major Pharmaceutical Preparations industry 13 other companies have achieved higher Net Income quarter on quarter growth. While Nature S Sunshine Products Inc 's Net Income growth quarter on quarter, overall rank is 1156.


Nature S Sunshine Products Inc 's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Jun 30 2024)
12 Months Ending
(Mar 31 2024)
12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
Cumulative Net Income 12 Months Ending $ 16.46 $ 17.65 $ 16.42 $ 9.16 $ 6.21
Y / Y Net Income Growth (TTM) 164.95 % 293.25 % 2884.73 % -25.37 % -64.55 %
Year on Year Net Income Growth Overall Ranking # 1171 # 973 # 1400 # 1211 # 1300
Seqeuential Net Income Change (TTM) -6.74 % 7.54 % 79.29 % 47.34 % 38.43 %
Seq. Net Income Growth (TTM) Overall Ranking # 289 # 17 # 1398 # 1084 # 901




Cumulative Net Income growth Comment
Assuming the Nature S Sunshine Products Inc 's fiscal year would have ended in Jun 30 2024, Nature S Sunshine Products Inc would have reprted above average annual Net Income surge of 164.95% year on year, of $ 16 millions.
This marks a slow-down of the companys growth trends and from the 293.25% surge in Mar 31 2024.

In the Healthcare sector 80 other companies have achieved higher trailing twelve month Net Income growth. While Net Income growth total ranking has deteriorated compare to previous quarter from 973 to 1171.

Net Income TTM Q/Q Growth Statistics
High Average Low
2884.73 %
68.95 %
-300.8 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 6
Healthcare Sector # 81
Overall # 1171

Net Income TTM Y/Y Growth Statistics
High Average Low
2884.73 %
68.95 %
-300.8 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 30
S&P 500 # 289
Cumulative Net Income growth Comment
Assuming the Nature S Sunshine Products Inc 's fiscal year would have ended in Jun 30 2024, Nature S Sunshine Products Inc would have reprted above average annual Net Income surge of 164.95% year on year, of $ 16 millions.
This marks a slow-down of the companys growth trends and from the 293.25% surge in Mar 31 2024.

In the Healthcare sector 80 other companies have achieved higher trailing twelve month Net Income growth. While Net Income growth total ranking has deteriorated compare to previous quarter from 973 to 1171.

Net Income TTM Q/Q Growth Statistics
High Average Low
2884.73 %
68.95 %
-300.8 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 6
Healthcare Sector # 81
Overall # 1171

Net Income TTM Y/Y Growth Statistics
High Average Low
2884.73 %
68.95 %
-300.8 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 30
S&P 500 # 289




Other Net Income Growth
Major Pharmaceutical Preparations Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
NATR's Net Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for NATR's Competitors
Net Income Growth for Nature S Sunshine Products Inc 's Suppliers
Net Income Growth for NATR's Customers

You may also want to know
NATR's Annual Growth Rates NATR's Profitability Ratios NATR's Asset Turnover Ratio NATR's Dividend Growth
NATR's Roe NATR's Valuation Ratios NATR's Financial Strength Ratios NATR's Dividend Payout Ratio
NATR's Roa NATR's Inventory Turnover Ratio NATR's Growth Rates NATR's Dividend Comparisons



Companies with similar Net Income surge for the quarter ending Jun 30 2024 within Healthcare SectorY/Y Change %Net Income for the quarter ending Jun 30 2024
Biogen Inc -1.63%$ -1.635 millions
Embecta Corp -3.29%$ -3.289 millions
Quest Diagnostics Inc-3.61%$ -3.614 millions
Abbott Laboratories-5.31%$ -5.309 millions
Zoetis Inc -6.87%$ -6.866 millions
Idexx Laboratories Inc-9.34%$ -9.337 millions
Prestige Consumer Healthcare Inc -11.89%$ -11.893 millions
Align Technology inc -13.64%$ -13.639 millions
National Research Corporation-15.10%$ -15.097 millions
Dariohealth Corp -17.94%$ -17.938 millions
Bristol myers Squibb Company-18.92%$ -18.922 millions
Organon and Co -19.42%$ -19.421 millions
U S Physical Therapy Inc-21.21%$ -21.206 millions
Fonar Corporation-25.01%$ -25.010 millions
Pacira Biosciences inc -26.69%$ -26.693 millions
Privia Health Group Inc -27.00%$ -26.997 millions
West Pharmaceutical Services Inc -28.24%$ -28.240 millions
Neurocrine Biosciences Inc -31.94%$ -31.937 millions
Abbvie Inc -32.26%$ -32.264 millions
Lifevantage Corp-33.62%$ -33.622 millions
Lantheus Holdings Inc -34.06%$ -34.057 millions
Viemed Healthcare Inc -36.61%$ -36.609 millions
Vaso Corporation-44.26%$ -44.257 millions
Nature s Sunshine Products inc -44.42%$ -44.415 millions
Royalty Pharma Plc-44.67%$ -44.675 millions
Globus Medical Inc -44.97%$ -44.968 millions
Amgen Inc -45.90%$ -45.903 millions
Elite Pharmaceuticals Inc -46.07%$ -46.070 millions
Surgery Partners Inc -50.78%$ -50.780 millions
Radnet Inc -52.29%$ -52.294 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com